guest ::
| Home > Publications database > Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study. > print |
| Home > Publications database > Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study. > print |
| 001 | 143745 | ||
| 005 | 20240229112606.0 | ||
| 024 | 7 | _ | |a 10.1158/1055-9965.EPI-18-1285 |2 doi |
| 024 | 7 | _ | |a pmid:31015200 |2 pmid |
| 024 | 7 | _ | |a 1055-9965 |2 ISSN |
| 024 | 7 | _ | |a 1538-7755 |2 ISSN |
| 024 | 7 | _ | |a altmetric:59501352 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-01314 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Grafetstätter, Mirja |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2019 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1567415463_29547 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a While enhanced platelet activation and a procoagulant state may drive lung cancer progression and metastases, less is known about their role in earlier phases of cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risk of lung cancer in the prospective EPIC-Heidelberg Study using a case-cohort design.Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n=2,480) and incident cases of lung cancer (n=190). Multivariable-adjusted Cox proportional hazards regression analyses were used to obtain Hazard Ratios (HRs) of lung cancer across quartiles of biomarker levels.Fibrinogen (HR highest vs. lowest quartile: 1.91 [95 % confidence interval: 1.09, 3.34]) and sP-Selectin (HR: 2.51 [1.39, 4.52]) were significantly associated with lung cancer risk in multivariable adjusted Cox regression models. Adding both biomarkers to the established PLCOm2012 algorithm, which alone showed a C-statistic of 0.788, led to a slight increment in lung cancer risk prediction, with a C-statistic of 0.814.Our findings indicate that enhanced platelet activation and a pro-coagulative state contribute to lung carcinogenesis.The present prospective study supports the hypothesis of increased coagulation being a possible driver of lung carcinogenesis, as strong positive associations were found between two procoagulative markers, sP-Selectin and fibrinogen, with lung cancer risk. Both biomarkers could improve lung cancer risk prediction, but external validation of the results is needed. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Hüsing, Anika |0 P:(DE-He78)6519c85d61a3def7974665471b8a4f74 |b 1 |u dkfz |
| 700 | 1 | _ | |a González Maldonado, Sandra |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Sookthai, Disorn |0 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be |b 3 |u dkfz |
| 700 | 1 | _ | |a Johnson, Theron S |0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |b 4 |u dkfz |
| 700 | 1 | _ | |a Pletsch-Borba, Laura |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 6 |u dkfz |
| 700 | 1 | _ | |a Hoffmeister, Michael |0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |b 7 |u dkfz |
| 700 | 1 | _ | |a Bugert, Peter |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 9 |u dkfz |
| 700 | 1 | _ | |a Kuehn, Tilman |0 P:(DE-HGF)0 |b 10 |e Last author |
| 773 | _ | _ | |a 10.1158/1055-9965.EPI-18-1285 |g p. cebp.1285.2018 - |0 PERI:(DE-600)2036781-8 |n 7 |p 1221-1227 |t Cancer epidemiology, biomarkers & prevention |v 28 |y 2019 |x 1538-7755 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:143745 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)6519c85d61a3def7974665471b8a4f74 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER EPIDEM BIOMAR : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l Epidemiologie von Krebserkrankungen |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l Klinische Epidemiologie und Alternsforschung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|